Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Drug companies call for antibiotic funding
Pills in bottle
Antibiotic resistance has increased so much in recent years that it is now considered to be a serious risk to public health.
Government urged to take urgent action

Pharmaceutical companies and industry bodies are warning of a "terrible human cost" unless new ways to fund antibiotics can be found.

In an open letter published in the Financial Times, the organisations urge the government to take urgent action. They also highlight warnings that around 10 million people a year could be killed by drug-resistant bacteria by 2050.

They write that without new antibiotics "everything from routine surgical procedures, to cancer chemotherapy, organ transplantation and even childbirth will become increasingly dangerous."

They add that if we fail to act now, "antimicrobial resistance is also expected to cost the world economy $100tn a year by 2050."

Antibiotic resistance has increased so much in recent years that it is now considered to be a serious risk to public health.

In 2014,the lack of existing antibiotics, together with the lack of new antibiotic treatments led the World Health Organisation to describe the situation as a "post-antibiotic era", where people can die from simple infections that have been treatable for decades.

The letter was signed by professor Colin Garner, chief executive of Antibiotic Research UK; prof Jayne Lawrence, chief scientist at the Royal Pharmaceutical Society; John Rex, a senior AstraZeneca executive; prof Luigi Martini, of King's College London; and Jeremy Lefroy MP.

The letter was also signed by Bioindustry Association chief executive Steve Bates, who told BBC News that companies' investment "needed to be rewarded," but without encouraging the overuse of antibiotics.

He suggested that the government set up a insurance-style scheme in which it paid a fixed fee for antibiotics, so that manufacturers didn't just focus on research into drugs that increased sales. 

Become a member or log in to add this story to your CPD history

Voting opens for BEVA Council

News Story 1
 Eligible members of BEVA will be able to vote for their Council team until Monday, 17 August 2026. Members will have received an election email on 17 July.

There are five candidates standing for four available places on Council. They are:

  • Alexandre Triguino
  • Angela Jones
  • Beth Bryant
  • Holly Rees
  • Hugh Somerville
Full profiles for each candidate can be found on the BEVA website

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'